D. Wells

David L. Thomas, M. Lythgoe, D. Gadian, 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Growth differentiation factor‐15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo

Claire E. Wells, M. Polkey, W. Man, 2015, Journal of cachexia, sarcopenia and muscle.

The Neuroprotective Effects of Heat Shock Protein 27 Overexpression in Transgenic Animals against Kainate-induced Seizures and Hippocampal Cell Death*

M. Akbar, D. Latchman, A. Lundberg, 2003, Journal of Biological Chemistry.

Focus on the Role of D-serine and D-amino Acid Oxidase in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS)

D. Wells, Ke Liu, J. Hildyard, 2018, Front. Mol. Biosci..

Microbubble stability is a major determinant of the efficiency of ultrasound and microbubble mediated in vivo gene transfer.

R. Eckersley, D. Wells, D. Lopes, 2009, Ultrasound in medicine & biology.

Efficiency of in vivo gene transfer using murine retroviral vectors is strain-dependent in mice.

A. Fassati, F. Walsh, G. Dickson, 1995, Human gene therapy.

Animal Research beyond the Laboratory: Report from a Workshop on Places Other than Licensed Establishments (POLEs) in the UK

M. Witt, Julie Lane, C. Newman, 2020, Animals : an open access journal from MDPI.

Electroporation for gene transfer to skeletal muscles: current status.

D. Wells, Jill McMahon, 2004, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Intramuscular injection of plasmid DNA.

D. Wells, 1995, Molecular and cell biology of human diseases series.

Poloxomer 188 Has a Deleterious Effect on Dystrophic Skeletal Muscle Function

D. Wells, R. Terry, H. Kaneb, 2014, PloS one.

Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy

D. Wells, K. Wells, A. Ferrer, 2000, Gene Therapy.

Tracking progress: an update on animal models for Duchenne muscular dystrophy

D. Wells, 2018, Disease Models & Mechanisms.

Identification of qPCR reference genes suitable for normalising gene expression in the developing mouse embryo

D. Wells, J. Hildyard, R. Piercy, 2020, bioRxiv.

INHERITED DISEASE RESEARCH ARTICLE Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy

D. Wells, K. Wells, A. Ferrer, 2000 .

Relocalization of neuronal nitric oxide synthase (nNOS) as a marker for complete restoration of the dystrophin associated protein complex in skeletal muscle

Susan C. Brown, F. Muntoni, Q. Lu, 2003, Neuromuscular Disorders.

Improving translational studies: lessons from rare neuromuscular diseases

D. Wells, 2015, Disease Models & Mechanisms.

Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo.

F. Walsh, G. Dickson, D. Wells, 1993, Human molecular genetics.

Investigation of a transgenic mouse model of familial dilated cardiomyopathy.

K. Clarke, M. Ferenczi, S. Harding, 2010, Journal of molecular and cellular cardiology.

Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.

S. Winder, D. Wells, C. Moore, 2012, Human molecular genetics.

Identification and Validation of Quantitative PCR Reference Genes Suitable for Normalizing Expression in Normal and Dystrophic Cell Culture Models of Myogenesis

D. Wells, J. Hildyard, 2014, PLoS currents.

Gene doping: the hype and the reality

D. Wells, D. Wells, 2008, British journal of pharmacology.

An IL-7 Fusion Protein That Shows Increased Thymopoietic Ability1

D. Wells, S. Henson, T. Hussell, 2005, The Journal of Immunology.

FHL1 activates myostatin signalling in skeletal muscle and promotes atrophy

D. Wells, Jen Y. Lee, P. Kemp, 2015, FEBS Open Bio.

Extracellular Release of the Atheroprotective Heat Shock Protein 27 Is Mediated by Estrogen and Competitively Inhibits acLDL Binding to Scavenger Receptor-A

K. Rayner, T. Simard, D. Wells, 2008, Circulation research.

Mice that overexpress human heat shock protein 27 have increased renal injury following ischemia reperfusion.

J. Belleroche, V. D’Agati, S. Park, 2009, Kidney international.

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment

R. Manzano, D. Tyler, S. Hammond, 2018, Human molecular genetics.

The skeletal muscle phenotype of the DE50-MD dog model of Duchenne muscular dystrophy

D. Wells, J. Hildyard, R. Piercy, 2022, Wellcome Open Research.

Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins

G. Dickson, D. Wells, H. Foster, 2004, Gene Therapy.

Evaluation of plasmid DNA for in vivo gene therapy: factors affecting the number of transfected fibers.

D. Wells, J. Maule, A. Poole, 1998, Journal of pharmaceutical sciences.

Rapid histological quantification of muscle fibrosis and lysosomal activity using the HSB colour space

D. Wells, J. Hildyard, R. Piercy, 2022, bioRxiv.

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy

K. Clarke, S. Hammond, M. Wood, 2015, Scientific Reports.

Histopathological Evaluation of Skeletal Muscle with Specific Reference to Mouse Models of Muscular Dystrophy

D. Wells, R. Terry, 2016, Current protocols in mouse biology.

What do animal models have to tell us regarding Duchenne muscular dystrophy?

D. Wells, K. Wells, Dominic J. Wells, 2005, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice.

I. Graham, F. Muntoni, G. Dickson, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Immune responses, not promoter inactivation, are responsible for decreased long‐term expression following plasmid gene transfer into skeletal muscle

D. Wells, K. Foster, J. Maule, 1997, FEBS letters.

Gene Therapy Clinical Trials for Muscular Dystrophies

D. Wells, 2010 .

What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?

D. Wells, 2019, Journal of Muscle Research and Cell Motility.

Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD?

D. Wells, K. Wells, 2002, Neuromuscular Disorders.

Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein–Barr virus (EBV)-based mini-chromosome vectors in mdx mice

G. Dickson, D. Wells, P. Strong, 1999, Gene Therapy.

Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells.

A. Fassati, F. Walsh, G. Dickson, 1997, The Journal of clinical investigation.

Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice.

K. Davies, F. Walsh, G. Dickson, 1992, Human molecular genetics.

A New Extensively Characterised Conditionally Immortal Muscle Cell-Line for Investigating Therapeutic Strategies in Muscular Dystrophies

D. Wells, J. Morgan, S. Muses, 2011, PloS one.

Insertion of two independent enhancers in the long terminal repeat of a self-inactivating vector results in high-titer retroviral vectors with tissue-specific expression.

N. Bresolin, A. Fassati, G. Dickson, 1998, Human gene therapy.

Longitudinal assessment of blood-borne musculoskeletal disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy

D. Wells, J. Hildyard, R. Piercy, 2021, Wellcome open research.

Differential expression and secretion of alpha 1 anti-trypsin between direct DNA injection and implantation of transfected myoblast

Q. Lu, D. Wells, George Bou-Gharios, 1999, Gene Therapy.

Expression of opsin genes early in ocular development of humans and mice.

R. Foster, J. Bellingham, M. Hankins, 2003, Experimental eye research.

Characterisation of the pathogenic effects of the in vivo expression of an ALS-linked mutation in D-amino acid oxidase: Phenotype and loss of spinal cord motor neurons

D. Wells, Ke Liu, J. Hildyard, 2017, PloS one.

Age and sex influence expression of plasmid DNA directly injected into mouse skeletal muscle

D. Wells, G. Goldspink, Geoffrey Goldspink, 1992, FEBS letters.

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

J. Bourke, K. Bushby, F. Muntoni, 2011, The Lancet.

Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy

D. Wells, J. Hildyard, 2016, PLoS currents.

Independent Regulation of the Myotonic Dystrophy 1 Locus Genes Postnatally and during Adult Skeletal Muscle Regeneration*

L. Edström, D. Watt, M. Anvret, 2000, The Journal of Biological Chemistry.

Molecular Mechanism of the E99K Mutation in Cardiac Actin (ACTC Gene) That Causes Apical Hypertrophy in Man and Mouse*

K. Clarke, L. Monserrat, S. Harding, 2011, The Journal of Biological Chemistry.

The Pen Is Milder Than the Blade: Identification Marking Mice Using Ink on the Tail Appears More Humane Than Ear-Punching Even with Local Anaesthetic

D. Wells, C. Burn, N. Chancellor, 2021, Animals : an open access journal from MDPI.

Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1G93A Mouse Model of ALS and Is Harmful in Female Mice

D. Wells, P. Sharp, H. Kaneb, 2011, PloS one.

Characterisation of expression of mDMAHP, a homeodomain-encoding gene at the murine DM locus.

D. Wells, K. Johnson, C. Hoyle, 1997, Human molecular genetics.

Gene Therapy Progress and Prospects: Electroporation and other physical methods

D. Wells, D J Wells, Dominic J. Wells, 2004, Gene Therapy.

Animal Technology and Welfare

A. Rice, D. Wells, M. Gardiner, 2011 .

Report of the 2005 RSPCA/UFAW Rodent Welfare Group meeting

D. Wells, R. Hubrecht, M. Maconochie, 2006, Lab Animal.

Electroporation and ultrasound enhanced non-viral gene delivery in vitro and in vivo

D. Wells, 2010, Cell Biology and Toxicology.

Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy

D. Wells, 2006, Journal of Muscle Research & Cell Motility.

Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice.

G. Dickson, D. Wells, S. Fabb, 2002, Human molecular genetics.

Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering

M. Duchen, O. Cappellari, D. Wells, 2018, Cell reports.

Improved gene transfer by direct plasmid injection associated with regeneration in mouse skeletal muscle

D. Wells, 1993, FEBS letters.

Ectopic Expression of NCAM in Skeletal Muscle of Transgenic Mice Results in Terminal Sprouting at the Neuromuscular Junction and Altered Structure But Not Function

F. Walsh, C. Hobbs, D. Wells, 2000, Molecular and Cellular Neuroscience.

Altered secondary myogenesis in transgenic animals expressing the neural cell adhesion molecule under the control of a skeletal muscle alpha-actin promoter

F. Walsh, C. Hobbs, D. Wells, 1996, The Journal of cell biology.

Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies.

Susan C. Brown, F. Muntoni, D. Wells, 2011, Current opinion in neurology.

Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy

A. Mayhew, E. Mercuri, K. Bushby, 2015, Neuromuscular Disorders.

Multiplex in situ hybridization within a single transcript: RNAscope reveals dystrophin mRNA dynamics

D. Wells, J. Hildyard, R. Piercy, 2019, bioRxiv.

Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy.

K. Campbell, Y. Sunada, F. Walsh, 1995, Human molecular genetics.

Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?

D. Wells, J. Hildyard, S. Brown, 2016, PloS one.

The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice.

Susan C. Brown, F. Muntoni, Jihee Kim, 2014, Human molecular genetics.

Evaluation of the effect of a transient up-regulation of LARGE in the mouse m.tibialis anterior

Martin Brockington, Francesco Muntoni, Sc Brown, 2006 .

Transgenic Overexpression of LARGE Induces α-Dystroglycan Hyperglycosylation in Skeletal and Cardiac Muscle

Susan C. Brown, F. Muntoni, D. Wells, 2010, PloS one.

Musculoskeletal magnetic resonance imaging in the DE50-MD dog model of Duchenne muscular dystrophy

D. Wells, R. Piercy, R. Drees, 2021, Neuromuscular Disorders.

Identification of the Key Regions within the Mouse Pro-α2(I) Collagen Gene Far-upstream Enhancer*

D. Abraham, T. Partridge, D. Wells, 2002, The Journal of Biological Chemistry.

Genetically modified animals and pharmacological research.

D. Wells, 2010, Handbook of experimental pharmacology.

Cooperativity between Far Upstream Enhancer and Proximal Promoter Elements of the Human α2(I) Collagen (COL1A2) Gene Instructs Tissue Specificity in Transgenic Mice*

D. Wells, George Bou-Gharios, Ke Liu, 2004, Journal of Biological Chemistry.

Structure and evolution of the teleost extraretinal rod-like opsin (errlo) and ocular rod opsin (rho) genes: is teleost rho a retrogene?

R. Foster, J. Bellingham, D. Wells, 2003, Journal of experimental zoology. Part B, Molecular and developmental evolution.

High-efficiency plasmid gene transfer into dystrophic muscle

D. Wells, K. Wells, J. McMahon, 2003, Gene Therapy.

Animal Models for Muscular Disorders

D. Wells, 2004 .

“Of Mice and Measures”: A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic

K. Davies, M. Girgenrath, C. Lutz, 2018, Journal of neuromuscular diseases.

Determination of qPCR Reference Genes Suitable for Normalizing Gene Expression in a Canine Model of Duchenne Muscular Dystrophy.

D. Wells, J. Hildyard, R. Piercy, 2018, Journal of neuromuscular diseases.

Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy

D. Wells, K. Wells, A. Ferrer, 2002, Expert Reviews in Molecular Medicine.

Mutated fukutin-related protein (FKRP) localises as wild type in differentiated muscle cells.

F. Muntoni, D. Wells, S. Torelli, 2005, Experimental cell research.

Identification of quantitative polymerase chain reaction reference genes suitable for normalising gene expression in the brain of normal and dystrophic mice and dogs

D. Wells, J. Hildyard, R. Piercy, 2021, Wellcome open research.

Identification of qPCR reference genes suitable for normalizing gene expression in the mdx mouse model of Duchenne muscular dystrophy

D. Wells, J. Hildyard, Amber M Finch, 2019, PloS one.

Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy

Annemieke Aartsma-Rus, O. Cappellari, D. Wells, 2020, Journal of neuromuscular diseases.

Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.

H. Bye-A-Jee, D. Wells, P. Sharp, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene delivery to dystrophic muscle.

D. Wells, H. Foster, K. Wells, 2008, Methods in molecular biology.

Exogenous Genes Are Expressed in mdx Muscle Fibres Following the Implantation of Primary Mouse Skin Cells

D. Watt, D. Wells, J. Relvas, 2007 .

Restoration of dystrophin expression using the Sleeping Beauty transposon

D. Wells, J. Morgan, S. Muses, 2011, PLoS currents.

Restoration of dystrophin expression using the Sleeping Beauty transposon.

D. Wells, J. Morgan, S. Muses, 2011, PLoS currents.

In silico characterisation and chromosomal localisation of human RRH (peropsin) – implications for opsin evolution

R. Foster, J. Bellingham, D. Wells, 2003, BMC Genomics.

Muscle moment arms and sensitivity analysis of a mouse hindlimb musculoskeletal model

John R. Hutchinson, Andrew J. Spence, James P. Charles, 2016, Journal of anatomy.

Serum inflammatory cytokines as disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy

D. Wells, J. Hildyard, R. Piercy, 2022, Disease models & mechanisms.

Mouse identification methods and potential welfare issues: a survey of current practice in the UK

D. Wells, C. Burn, N. H. Mazlan, 2014 .

Influence of needle gauge on in vivo ultrasound and microbubble-mediated gene transfection.

Helen Mulvana, Dominic J Wells, Jo V Hajnal, 2011, Ultrasound in medicine & biology.

The human ClC‐4 protein, a member of the CLC chloride channel/transporter family, is localized to the endoplasmic reticulum by its N‐terminus

C. Higgins, K. Weylandt, A. Sardini, 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

endothelial cell protein C receptor gene Role of a 5' -enhancer in the transcriptional regulation of the human

J. Landry, P. Cockerill, D. Wells, 2012 .

Heat shock protein 27 shows a distinctive widespread spatial and temporal pattern of induction in CNS glial and neuronal cells compared to heat shock protein 70 and caspase 3 following kainate administration.

M. Akbar, D. Latchman, D. Wells, 2001, Brain research. Molecular brain research.

Genetic engineering in athletes

D. Wells, 2008, BMJ : British Medical Journal.

Characterization of an Evolutionarily Conserved Far-upstream Enhancer in the Human α2(I) Collagen (COL1A2) Gene*

C. Denton, D. Wells, George Bou-Gharios, 2001, The Journal of Biological Chemistry.

Olfaction variation in mouse husbandry and its implications for refinement and standardization: UK survey of animal scents

D. Wells, C. Burn, Lucy E Whitfield, 2016, Laboratory animals.

Olfactory variation in mouse husbandry and its implications for refinement and standardization: UK survey of non-animal scents

D. Wells, C. Burn, Lucy E Whitfield, 2016, Laboratory animals.

Musculoskeletal Geometry, Muscle Architecture and Functional Specialisations of the Mouse Hindlimb

John R. Hutchinson, Andrew J. Spence, James P. Charles, 2016, PloS one.

Heat Shock Protein 27 Protects Against Atherogenesis via an Estrogen-Dependent Mechanism: Role of Selective Estrogen Receptor Beta Modulation

K. Rayner, T. Simard, D. Wells, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.

S. Tabrizi, R. Morimoto, D. Latchman, 2007, Human molecular genetics.

Heat shock protein 27 rescues motor neurons following nerve injury and preserves muscle function

J. Belleroche, D. Wells, P. Sharp, 2006, Experimental Neurology.

The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development

J. Mendell, K. Bushby, K. Flanigan, 2015, Neuromuscular Disorders.

A decade of optimizing drug development for rare neuromuscular disorders through TACT

A. Mayhew, M. Grounds, N. Goemans, 2019, Nature Reviews Drug Discovery.

Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.

D. Wells, K. Wells, A. Ferrer, 2000, Gene therapy.

Zebrafish melanopsin: isolation, tissue localisation and phylogenetic position.

A. Philp, R. Foster, J. Bellingham, 2002, Brain research. Molecular brain research.

Treatments for muscular dystrophy: Increased treatment options for Duchenne and related muscular dystropies

D. Wells, 2008, Gene Therapy.

Förster resonance energy transfer imaging in vivo with approximated radiative transfer equation.

Romain F. Laine, S. Arridge, J. Hajnal, 2011, Applied optics.

Systemic AAV Gene Therapy Close to Clinical Trials for Several Neuromuscular Diseases.

D. Wells, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Opening the floodgates: clinically applicable hydrodynamic delivery of plasmid DNA to skeletal muscle.

D. Wells, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

I. Graham, F. Muntoni, P. Nihoyannopoulos, 2009, The Lancet. Neurology.

Animal welfare and the 3Rs in European biomedical research

D. Wells, 2011, Annals of the New York Academy of Sciences.

Translational and regulatory challenges for exon skipping therapies.

A. Ferlini, Annemieke Aartsma-Rus, N. Goemans, 2014, Human gene therapy.

Improving translational studies: lessons from rare neuromuscular diseases

D. Wells, 2015, Disease Models & Mechanisms.

What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?

D. Wells, 2019, Journal of Muscle Research and Cell Motility.

Determination of qPCR Reference Genes Suitable for Normalizing Gene Expression in a Canine Model of Duchenne Muscular Dystrophy.

D. Wells, J. Hildyard, R. Piercy, 2018, Journal of neuromuscular diseases.

Identification of a Repressor in the First Intron of the Human α2(I) Collagen Gene (COL1A2)*

D. Wells, George Bou-Gharios, Ke Liu, 2005, Journal of Biological Chemistry.

Peptide-conjugated antisense therapy takes a skip ahead.

D. Wells, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Investigation of a mouse model of familial DCM with ACTC E361G mutation

K. Clarke, S. Harding, C. Carr, 2008 .

Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy

D. Wells, J. Hildyard, R. Piercy, 2022, Disease models & mechanisms.

Musculoskeletal magnetic resonance imaging in the DE50-MD dog model of Duchenne muscular dystrophy

D. Wells, R. Piercy, R. Drees, 2021, Neuromuscular Disorders.

D39 Characterising the skeletal muscle histological phenotype of the DeltaE50-MD dog, a preclinical model of Duchenne muscular dystrophy

D. Wells, J. Hildyard, R. Piercy, 2018, Neuromuscular Disorders.

Viral and non-viral methods for gene transfer into skeletal muscle.

D. Wells, 2006, Current opinion in drug discovery & development.

Enhanced gene transfection in vivo using magnetic localisation of ultrasound contrast agents: Preliminary results

E. Stride, Q. Pankhurst, J. Hajnal, 2010, 2010 IEEE International Ultrasonics Symposium.